Construction, Validation, and Visualization of Two Web-Based Nomograms to Predict Overall and Cancer-Specific Survival in Patients with Gastric Cancer and Lung Metastases

Table 2

Baseline data of clinicopathological characteristics of patients with GCLM in CSS group.

Variables	Total cohort (N = 524)		Training cohort (N = 368)		Validation cohort (N = 156)
	n	%	n	%	n	%
Age
<60	197	37.6	131	35.6	66	42.3
≥60	327	62.4	237	64.4	90	57.7
Race
Black	67	12.8	50	13.6	17	10.9
Other	69	13.2	49	13.3	20	12.8
White	388	74	269	73.1	119	76.3
Sex
Female	162	30.9	109	29.6	53	34.0
Male	362	69.1	259	70.4	103	66.0
Histologic type
Adenocarcinoma	340	64.9	247	67.1	93	59.6
Signet ring cell	76	14.5	46	12.5	30	19.2
Intestinal type	36	6.9	26	7.1	10	6.4
Other	72	13.7	49	13.3	23	14.7
T stage
T1	209	39.9	148	40.2	61	39.1
T2	36	6.9	27	7.3	9	5.8
T3	117	22.3	84	22.8	33	21.2
T4	162	30.9	109	29.6	53	34.0
N stage
N0	207	39.5	144	39.1	63	40.4
N1	254	48.5	187	50.8	67	42.9
N2	26	5	14	3.8	12	7.7
N3	37	7.1	23	6.3	14	9.0
Grade
Grade I	19	3.6	15	4.1	4	2.6
Grade II	147	28.1	105	28.5	42	26.9
Grade III	349	66.6	242	65.8	107	68.6
Grade IV	9	1.7	6	1.6	3	1.9
Bone metastasis
No	432	97.1	303	82.3	129	82.7
Yes	92	2.9	65	17.7	27	17.3
Liver metastasis
No	257	49	179	48.6	78	50.0
Yes	267	51	189	51.4	78	50.0
Brain metastasis
No	509	97.1	356	96.7	153	98.1
Yes	15	2.9	12	3.3	3	1.9
Primary site
Cardia	240	45.8	164	44.6	76	48.7
Fundus	33	6.3	22	6	11	7.1
Body	38	7.3	29	7.9	9	5.8
Gastric antrum	63	12	46	12.5	17	10.9
Lesser	20	3.8	11	3	9	5.8
Greater	24	4.6	19	5.2	5	3.2
Other	106	20.2	77	20.9	29	18.6
Radiotherapy
No	401	76.5	276	75	125	80.1
Yes	123	23.5	92	25	31	19.9
Chemotherapy
No	205	39.1	158	42.9	47	30.1
Yes	319	60.9	210	57.1	109	69.9
Surgery
No	481	91.8	340	92.4	141	90.4
Yes	43	8.2	28	7.6	15	9.6
Marital status
No	209	39.9	152	41.3	57	36.5
Yes	315	60.1	216	58.7	99	63.5
Insurance
No	31	5.9	22	6	9	5.8
Yes	493	94.1	346	94	147	94.2